科研之友
微信
新浪微博
Facebook
分享链接
摘要
Several studies have suggested that neurotensin receptors (NTRs) and neurotensin (NT) greatly affect the growth and survival of pancreatic ductal adenocarcinoma (PDAC). Developing NTR-targeted PET probes could therefore be important for the management of a pancreatic cancer patient by providing key information on the NTR expression profile noninvasively. Despite the initial success on the synthesis of F-18-labeled NT PET probes, the labeling procedure generally requires lengthy steps including azeotropic drying of F-18. Using a straightforward chelation method, here we report the simple preparation of aluminum-F-18-NOTA-NT starting from aqueous F-18. The cell binding test demonstrated that [F-19]AlF-NOTA-NT maintained high receptor-binding affinity to NTR1. This probe was then further evaluated in NTR1 positive pancreatic tumor models (AsPC-1 and PANC-1). After the administration of [F-18]AlF-NOTA-NT, small animal PET studies showed a high contrast between tumor and background in both models at 1 and 4 h time points. A blocking experiment was performed to demonstrate the receptor specificity: the tumor uptake in AsPC1 without and with blocking agent was 1.0 +/- 0.2 and 0.1 +/- 0.0%ID/g, respectively, at 4 h post injection. In summary, a NTR specific PET agent, [F-18]AlF-NOTA-NT, was prepared through the simple chelation method. This NTR-targeted PET probe may not only be used to detect NTR1 positive pancreatic tumors (diagnosis), but also it may be fully integrated to NTR target therapy leading to personalized medicine (theranostic).
